Results 41 to 50 of about 49,817 (284)

Responsiveness of the EuroQoL 5-Dimension (EQ-5D) questionnaire in patients with spondyloarthritis

BMC Musculoskeletal Disorders, 2021
Background Spondyloarthritis (SpA) has a significant impact on patients’ quality of life due to functional impairments. Generic health instruments like the EuroQoL 5-dimension (EQ-5D) is important for cost-utility analysis of health care interventions ...
Helen Hoi Lun Tsang, Carlos King Ho Wong, Prudence Wing Hang Cheung, Chak Sing Lau, Ho Yin Chung, Jason Pui Yin Cheung   +5 more
doaj   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

Arthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park, Sung‐Eun Choi, Ji‐Hyoun Kang, Jung‐Yoon Choe, Hye‐Soon Lee, So‐Young Bang, Yun‐Hong Cheon, Sang‐Il Lee, Mingyo Kim, Yoon‐Kyoung Sung, Soo‐Kyung Cho, Jae Hyun Jung, Sung Hae Chang, Sung Won Lee, Yeon‐Ah Lee, Seung‐Geun Lee, Hyun‐Sook Kim, Seung‐Ki Kwok, Seung‐Cheol Shim, Shin‐Seok Lee   +19 more
wiley   +1 more source

Dimensions of quality of life in patients with heart failure and sarcopenia: a scoping review protocol

Geriatrics, Gerontology and Aging
Objective: To map the dimensions of quality of life in patients with heart failure (HF) and sarcopenia. Methods: The scoping review will adhere to the JBI Manual for Evidence Synthesis methodology and will be reported following the Preferred Reporting ...
Valéria Gonçalves da Silva, Ana Carla Dantas Cavalcanti, Helena Cramer Veiga Rey, Eliza de Oliveira Barauna, Simone Pereira Lermontov   +4 more
doaj   +1 more source

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source

Mean summary scores of the EuroQol-5D-3L questionnaire and patients reporting symptoms on the Impast of Event Scale.

, 2020
Mean summary scores of the EuroQol-5D-3L questionnaire and patients reporting symptoms on the Impast of Event Scale.
Mariska A. C. de Jongh (6095867), Leonie de Munter (6095858), Cornelis L. P. van de Ree (8741349), Nena Kruithof (8741346), Koen W. W. Lansink (8741352), Suzanne Polinder (360134)   +5 more
core   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

RELATIONSHIP BETWEEN PHYSICAL ACTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN ELDERLY PEOPLE: A CROSS SECTION STUDY

Sanamed, 2017
Objectives: This study aimed to investigate the relationship between physical activitylevel and health related quality of life in elderly people. Design: Between January and April 2017, a cross-sectional study of 114 elderly people (73 males and 41 ...
Walid Kamal M. Abdelbasset, Gopal Nambi S   +1 more
doaj   +1 more source

Prevalence of moderate or severe problems (%) on each EuroQol-5D-3L dimension up until 2 years of follow-up.

, 2020
Prevalence of moderate or severe problems (%) on each EuroQol-5D-3L dimension up until 2 years of follow-up.
Mariska A. C. de Jongh (6095867), Leonie de Munter (6095858), Cornelis L. P. van de Ree (8741349), Nena Kruithof (8741346), Koen W. W. Lansink (8741352), Suzanne Polinder (360134)   +5 more
core   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Clinical features of the postictal state in adults with epilepsy: A cross‐sectional survey

Epilepsia, EarlyView.
Abstract Objective Persons with epilepsy may experience many postictal symptoms after a seizure, which can significantly impact quality of life. We aimed to determine the frequency, duration, and severity of postictal symptoms to better characterize the postictal period.
Ann Subota, Sundus Khan, Sara Lukmanji, Jeanie Y. Y. Lee, Meng Wang, Pamela Roach, Samuel Wiebe, Paolo Federico, Jeffrey Buchhalter, G. Campbell Teskey, Shaily Singh, Colin Bruce Josephson, Nathalie Jetté   +12 more
wiley   +1 more source